74 results about "5-Hydroxytryptophan" patented technology

This invention provides methods and compositions for incorporation of an unnatural amino acid into a peptide using an orthogonal aminoacyl tRNA synthetase / tRNA pair. In particular, an orthogonal pair is provided to incorporate 5-hydroxy-L-tryptophan in a position encoded by an opal mutation.

This invention relates to novel pharmaceutical compositions comprising a therapeutically effective amount of a slow-release formulation of 5-hydroxytryptophan (5-HTP) and a serotonin-enhancing compound. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating CNS disorders, including depressive disorders, bipolar disorders, anxiety disorders, obesity and pain.

A composition and method for treating Attention Deficit / Hyperactivity Disorder (ADHD) is provided which can be used both with and without ethical drugs now used to treat ADHD. The composition contains dimethylaminoethanol (DMAE), omega 3-fatty acids, betaine, oligomeric proanthocyanidins (OPC), folic acid, vitamins C, E, B12, B6, B5 and beta-carotene and minerals (calcium, magnesium, zinc and selenium). Ethical drugs such as amphetamines, methylphenidate HCl and pemoline are known to control ADHD, but each has significant side effects when used in their therapeutic dose. When combining the composition with such ethical drugs, the amount of the ethical drug can be lowered below a level which causes undesirable side effects which is an important feature. Preferred compositions contain one or more of lecithin, choline, 5-hydroxytryptophan, tyrosine, Reishi Extract, Kava Extract, Gingko, Ginseng and St. John's Wort.

Described herein is a low-glycemic nutritional supplement to be incorporated into the diet of an overweight or obese patient comprising low glycemic index ingredients including carbohydrate source, a source of protein, and a source of fat, and further comprising a source of green tea extract, a source of 5-hydroxytryptophan (5-HTP), and a source of chromium. The supplement provides active food-grade ingredients to improve the management weight loss, prevention of weight gain, and a feeling of satiety.

An orally or parenterally administered composition for reducing the storage of lipids in a human, the composition comprising: an effective amount of hydroxycitric acid; an effective amount of carnitine; an effective amount of biotin; an effective amount of one or more gluconeogenic substrates selected from the group consisting of: aspartate, lactate, glycerol, and a gluconeogenic amino acid or alphaketo analogue thereof; an effective amount of eicosapentanoic acid; and an effective amount of one or more ingredients selected from the group consisting of: medium chain triglycerides (MCT) with fatty acid backbones containing 6 to 14 carbon atoms or their individual fatty acid analogues or metabolic precursors, sesame seeds or derivative products, sesamin and / or its epimer episesamin, caffeine, forskolin, 7-keto dehydroepiandrosterone (7-keto DHEA), green tea extract containing epigallocatechingallate (EGCG), capsaicum, and 5-hydroxytryptophan (5-HTP). The supplement may also be combined with a food, beverage, condiment, spice or salad dressing base to provide a food, beverage, condiment, spice or salad dressing product designed to reduce lipid storage.

The present invention relates to a nutritional supplement composition, comprising a therapeutically effective amounts of Vitamin C, Vitamin D3, Thiamin, Riboflavin, Niacin, Vitamin B6, Folic acid, Vitamin B12, Pantothenic acid, Calcium, Magnesium, Zinc, Chromium, Sugar, Protein, Acetyl-L-Carnitine, Dimethylaminoethanol complex, Phosphatidylserine complex, L-Glutamine, N-Acetyl-L-Tyrosine, L-Phenylalanine, Taurine, Methionine, Valine, Isoleucine, 5 Hydroxytryptophan, L-Taurine, N-Acetyl-Tyrosine, N-Acetyl-L-Cysteine, Alpha Lipoic Acid, Alpha Glycerylphosphoricholine complex, Bacopa Monnieri extract, Gingko Biloba extract, Passion flower, Lemon Balm, Gotu Kola, Ashwagandha, Choline Bitartrate complex, Panax Ginseng extract, Turmeric, Organic freeze dried fruit juice blends (concord grape, red raspberry, pineapple, cranberry, acai, pomegranate, acerola cherry, bilberry, lingonberry, black currant, aronia, sour cherry, black raspberry), Organic freeze dried greens blends (barley grass, broccoli, beet, carrot, alfalfa, oat), and Protein digestive enzyme blends (Protease 4.5, peptidase, bromelain, protease 6.0, protease 3.0, L planatrum, B bifidum) in a mixture to provide optimal cognitive function.

The mechanism of the UV light-induced reaction between the indole moiety of tryptophan and chloroform, and the structure of the modified tryptophan and polypeptides including such modified tryptophan residues. The excited indole moiety, which is formed upon UV light irradiation, emits a solvated electron which initiates a series of events that yield fluorescent derivatives that have CHO group covalently bound to the indole moiety. These derivatives are herein referred to as formyltryptophan, and are relatively stable. Similar reactions are observed when 5-hydroxytryptophan, 5-fluorotryptophan, or N-methylindolacetate are used in place of tryptophan, or when other haloalkanes, such as trichloracetic acid, trichlorethanol, trichlorethane, bromoform, and iodoactetate are used in place of chloroform. The derivatives can be used in a variety of applications in fluorescence spectroscopy, and for nuclear magnetic resonance, X-ray crystallography, infra-red spectroscopy, circular dicroism and mass spectroscopy. Additionally, the UV light-induced reaction between the indole moiety of tryptophan and haloalkanes can be used to prepare derivatives of tryptophan for chemical cross-linking studies of proteins and peptides.

New controlled-release formulations containing tryptophan and / or its metabolites are described, as well as the process to obtain them in tablet forms suitable for oral administration in the treatment of pathologies or conditions related to serotonin deficiency in the Nervous System. The formulations are comprised in double-layer tablets, one layer containing 5-hyrohytryptophan released rapidly (phase “fast), the other layer containing tryptophan or 5-hydroxytryptophan, progressively released (“retarded”). The finished product is characterized by optimal differential release profile under physiological conditions. In all cases the release kinetics obtained is accurately time- and concentration-controlled, therefore avoiding fortuitous release of the active ingredients, and in clinical setting is free of undesirable side effects.

The mechanism of the UV light-induced reaction between the indole moiety of tryptophan and chloroform, and the structure of the modified tryptophan and polypeptides including such modified tryptophan residues. The excited indole moiety, which is formed upon UV light irradiation, emits a solvated electron which initiates a series of events that yield fluorescent derivatives that have CHO group covalently bound to the indole moiety. These derivatives are herein referred to as formyltryptophan, and are relatively stable. Similar reactions are observed when 5-hydroxytryptophan, 5-fluorotryptophan, or N-methylindolacetate are used in place of tryptophan, or when other haloalkanes, such as trichloracetic acid, trichlorethanol, trichlorethane, bromoform, and iodoactetate are used in place of chloroform. The derivatives can be used in a variety of applications in fluorescence spectroscopy, and for nuclear magnetic resonance, X-ray crystallography, infra-red spectroscopy, circular dicroism and mass spectroscopy. Additionally, the UV light-induced reaction between the indole moiety of tryptophan and haloalkanes can be used to prepare derivatives of tryptophan for chemical cross-linking studies of proteins and peptides.

The invention discloses blood pressure reducing and sleeping promoting health-care food. The health-care food comprises oligosaccharide, gamma-aminobutyric acid, theanine, taurine, 5-hydroxytryptophan, minerals and vitamins. The health-care food is reasonable in prescription and rich in nutrients, and can be used for effectively relieving physical and psychological stress, relaxing mind, promoting sleeping and reducing blood pressure.

The comprehensive pharmacologic therapy for treatment of obesity including Cysteine is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and / or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, Cysteine, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.

The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of ω-3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof; of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof.

A method of treating a human subject suffering from obesity or who simply desires to lose weight is disclosed, which comprises administering to the subject an effective amount of a compound which enhances serotonin, noradrenaline, and adrenaline activity. The formula is comprised of effective amounts of caffeine, L-phenylalanine, and one or more of L-tryptophan and 5-hydroxytryptophan.

The invention provides a production process for extracting and preparing high-purity 5-hydroxytryptophan from Griffonia simplicifolia, belonging to the technical content of extracting 5-hydroxytryptophan from plants and solving the problems of low yield, low purity and influence on product quality, low extraction speed and the like due to variegation generated by other pigment in the process of extracting 5-hydroxytryptophan from plants in the prior art. The production process comprises the following steps: using Griffonia simplicifolia produced in Africa as raw material, carrying out supercritical extraction for degreasing, extracting the degreased material for 3-5 times by using water or alcoholic solvents or mixed solution of water and alcoholic solvents; merging the extraction solution, carrying out microfiltration, ultrafiltration, adsorption by using ion exchange resin, elution, vacuum concentration, lower-temperature crystallization, centrifugal separation and microwave drying to obtain high-purity 5-hydroxytryptophan dry powders. The process has the advantages of rapidness, high efficiency, high yield, good quality and the like, and is suitable for large-scale industrial production; and the purity of the obtained product can reach more than 99.5 percent, and the yield is more than 90 percent.

The comprehensive pharmacologic therapy for treatment of obesity is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and / or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.

The invention discloses a composition comprising melatonin, gamma-aminobutyric acid, instant asparagus powder, platycladi seeds, vitamin B6, 5-hydroxytryptophan, theanine and semen ziziphi spinosae and the like. The composition can remarkably improve exercise-induced insomnia.

The comprehensive pharmacologic therapy for treatment of obesity including Cysteine is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and / or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, Cysteine, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.

Embodiments of the present invention relate to a nutritional sleep supplement having a balanced ratio of nutritional elements to facilitate a healthy lifestyle. In one embodiment, a nutritional sleep supplement has a set of active ingredients, the active ingredients comprising: between 50 mg to 600 mg of 5-Hydroxytryptophan; between 125 mg to 1500 mg of calcium lactate; between 50 mg to 600 mg of citric acid; between 125 mg to 1500 mg of gamma-Aminobutyric acid; between 50 mg to 600 mg of L-theanine; between 25 mg to 300 mg of L-tryptophan; between 45 mg to 540 mg of magnesium glycinate; between 1.25 mg to 15 mg of melatonin; between 8.75 mg to 105 mg of niacin; between 7.5 mg to 90 mg of potassium sorbate; and between 10 mg to 100 mg of pyridoxine.

The invention provides compounds, compositions, non-naturally occurring organisms, and methods useful for production of 5-hydroxytryptophan (5-HTP) in a microbial cell. A microbial system which includes at least one microbial cell, such as a bacterial cell or a yeast cell, is genetically engineered to express all or a portion of non-naturally occurring biosynthetic pathway that catalyzes the conversion of a simple carbon source, such as glucose, to 5-HTP. The invention can result in improved titers of 5-HTP and permits low-cost, large scale production. Methods of making and using the genetically engineered cells are also included in the invention.

The invention provides a preparation method of levo-5-hydroxytryptophan. The method comprises the following steps: performing methyl esterification / ethyl esterification on L-tryptophan to obtain L-tryptophan methyl / ethyl ester hydrochloride, performing dehydrochlorination under the alkaline condition to obtain L-tryptophan methyl / ethyl ester, performing acetylation to obtain N-acetyl-L-tryptophanmethyl / ethyl ester, reducing an indole ring under a triethylsilane-trifluoroacetic acid reduction system, oxidizing 1-position nitrogen of the indole ring under a sodium tungstate-30% hydrogen peroxide system, finally removing acetyl protection group to obtain levo-5-hydroxytryptophan under the acidic condition, further cooling and crystallizing, then enabling mother liquor to pass through a macroporous adsorption resin column, performing concentration, cooling and crystallization, and combining obtained levo-5-hydroxytryptophan crystals. The process has the advantages of being low in price of raw materials, being easy to obtain the raw materials, being simple in reaction operation, being high in yield, being good in product quality, being low in environmental pollution and the like, and is suitable for industrial large-scale production, the purity of the obtained product can achieve 99.2%, and the total yield is above 45%.

The present invention relates to combination therapies and pharmaceutical compositions comprising a combination of 5-hydroxytryptophan and a serotonin reuptake inhibitor. The present invention provides a pharmaceutical composition comprising (i) a serotonin reuptake inhibitor and (ii) 5-hydroxytrytophan. The present invention further provides a pharmaceutical composition comprising (i) 5-hydroxytryptophan in an amount ranging from about 1 mg to about 75 mg; and (ii) a serotonin reuptake inhibitor. The present invention also provides a pharmaceutical composition comprising (i) a subclinical dose of a serotonin reuptake inhibitor; and (ii) 5-hydroxytryptophan.

The invention relates to a method for extracting 5-hydroxytryptophan. The method has the advantages that: the yield of the product is improved and the energy consumption is reduced because an antioxidant is added to protect and an ion exchange resin and a macroporous resin are combined. The method comprises the following steps of: crushing a raw material, namely griffonia seeds, soaking the raw material into acidic water and sodium pyrosulfite for extraction for 2 to 3 times, wherein the amount of the acidic water and the amount of the sodium pyrosulfite are both 8 to 15 times that of the raw material and the raw material is soaked for 4 to 10 hours at each time, adsorbing the extract by adding the extract into a cation exchange resin column, washing the extract with deionized water until the extract is colorless, eluting the extract with aqueous ammonia (containing 0.1 to 0.3 percent of sodium metabisulfite) of which the concentration is 10 to 15 percent, adjusting the pH value of the eluate to 2 to 4, adsorbing the eluate by adding the eluate into a macroporous resin column, washing the eluate with water until the eluate is neutral, eluting the effective component with 4-6 BV ethanol solution of which the concentration is 40 to 60 percent, collecting the eluate, adding the eluate into active carbon to decolor the eluate, reclaiming the ethanol, concentrating the decoloring liquid until the concentration of the decoloring liquid is 1.4 to 1.6, placing the decoloring liquid until the decoloring liquid is crystallized, filtering the crystal, and drying the crystal to obtain the product. The method is simply operated and is suitable for industrial production.

Recombinant microbial cells and methods for producing 5-hydroxytryptophan (5HTP) using such cells are described. More specifically, the recombinant microbial cell comprises an exogenous gene encoding an L-tryptophan hydroxylase, and means for providing tetrahydrobiopterin (THB). Related sequences and vectors for use in preparing such recombinant microbial cells are also described.

The invention relates to a new synthetic method of a PET imaging agent L-5-<18>FETP. The method comprises the following steps: (a) carrying out a reaction between 5-hydroxytryptophan and C<1-3>alkylolto obtain a product; carrying out a reaction between the product and di-tert-butyl (i.e. (BOC)2O) to obtain N-BOC-L-5-hydroxytryptophan; (b) fluorizating 1,2-glycol tosylate in the presence of the ions such as potassium carbonate, Kryptate2.2.2 and <18>F<-> to obtain 2-<18F>-fluoroethanol p-toluene sulphonic acid ester (i.e. <18>FCH2CH2OTs); (c) carrying out a reaction between the 2-<18F>-fluoroethanol p-toluene sulphonic acid ester and the alkali metal salt of the N-BOC-L-5-hydroxytryptophan (such as sodium salt) to obtain O-(2-<18F>fluoroethyl)-N-BOC-L-5-hydroxytryptophan; (d) hydrolyzing the O-(2-<18F>fluoroethyl)-N-BOC-L-5-hydroxytryptophan under acidic conditions to remove an amino group and a carboxy protective group and obtain a final product of O-(2-<18F>fluoroethyl)-N-BOC-L-5-hydroxy tryptophan; and (e) purifying the product. The method greatly improves the radiochemical yield, obtains a sufficient quantity of a target product and realizes the clinical application of the target product.

This invention relates to novel pharmaceutical compositions comprising a therapeutically effective amount of a slow-release formulation of 5-hydroxytryptophan (5-HTP) and a serotonin-enhancing compound. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating CNS disorders, including depressive disorders, bipolar disorders, anxiety disorders, obesity and pain.

The present disclosure is a composition, a method of making the composition and method of using such composition preferably in the form of a dietary supplement that, when administered, is capable of treating insomnia and other sleep-related disorders. The unique combination of the composition is preferably administered orally. The composition is preferably comprised of at least vitamin B6, chamomile extract, passionflower extract, lemon balm extract, L-Theanine, GABA, 5-Hydroxytryptophan, and melatonin, in pre-determined amounts. The composition can further comprise a palliative agent, and can be provided in the form of a capsule, powder, liquid or tablet.

The invention provides a novel extraction and purification technology for 5-hydroxytryptophan. The novel extraction and purification technology mainly comprises the following steps of: (1) squeezing griffonia simplicifolia seeds to remove oil; (2) extracting cake feeds; (3) concentrating an extracting solution, and degreasing; (4) crystallizing a concentration solution; (5) centrifuging crystal substances and drying; and (6) preprocessing crystallizing mother liquor. Especially, the crystallizing mother liquor is treated by four methods, so that scarce resources are effectively utilized, and the yield is increased, and the total yield can be up to 12.5%. An anti-oxidant treatment technology is adopted in squeezing and extraction processes; the novel extraction and purification technology is advanced and unique, has the advantages of mild extraction conditions, high extraction ratio, low production cost, high yield and simple and convenient operation, and is environment-friendly and suitable for industrial production; and raw materials are saved in the whole productive process.